Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS — Stella

Recruiting

Back to aHUS trials

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(12 sites)

Japan

Research Site, Bunkyō City

Research Site, Hirakata-shi

Research Site, Iruma-Gun

Research Site, Kyoto

Research Site, Matsumoto-shi

Key details

Phase

Post-approval study

Sponsor

Alexion Pharmaceuticals, Inc.

Enrollment target

~20 participants

Started

December 2025

Primary completion

June 2027

Age range

18 Years and older

Last updated January 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov